Thrombospondin-1 promotes matrix homeostasis by interacting with collagen and lysyl oxidase precursors and collagen cross-linking sites by Rosini, Silvia et al.
                          Rosini, S., Pugh, N., Bonna, A. M., Hulmes, D. J. S., Farndale, R. W., &
Adams, J. C. (2018). Thrombospondin-1 promotes matrix homeostasis by
interacting with collagen and lysyl oxidase precursors and collagen cross-
linking sites. Science Signaling, 11(532), [eaar2566].
https://doi.org/10.1126/scisignal.aar2566
Peer reviewed version
Link to published version (if available):
10.1126/scisignal.aar2566
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via AAAS at  http://stke.sciencemag.org/content/11/532/eaar2566 . Please refer to any applicable terms of use
of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1 
 
 
Thrombospondin-1 promotes matrix homeostasis by interacting with 
collagen and lysyl oxidase precursors and collagen cross-linking sites** 
 
Silvia Rosini1$, Nicholas Pugh2^, Arkadiusz M. Bonna2, David J. S. Hulmes3, Richard 
W. Farndale2+, Josephine C. Adams1+*  
1School of Biochemistry, University of Bristol, Bristol, BS8 1TD, UK 
2Dept. of Biochemistry, University of Cambridge, Cambridge, CB1 1QW, UK 
3Tissue Biology and Therapeutic Engineering unit (LBTI), UMR5305 CNRS/University of 
Lyon I, 69367 LYON cedex 07, France 
 
$Current address: Faculty of Biology, Medicine and Health, AV Hill Building, The University 
of Manchester, Oxford Road, Manchester, M13 9PT, UK. 
 
^Current address: Department of Biomedical and Forensic Sciences, Anglia Ruskin 
University, Cambridge, CB1 1PT, UK  
+ Joint senior authors 
*Author for manuscript correspondence: jo.adams@bristol.ac.uk 
 
**This manuscript has been accepted for publication in Science Signaling. This version has not 
undergone final editing. Please refer to the complete version of record 
at http://www.sciencesignaling.org/. The manuscript may not be reproduced or used in any manner 
that does not fall within the fair use provisions of the Copyright Act without the prior, written 
permission of AAAS. 
 
 
 
ABSTRACT  
Fibrillar collagens of the extracellular matrix are critical for tissue structure and physiology, 
yet excessive or abnormal deposition of collagens is a defining feature of fibrosis. Regulatory 
mechanisms that act on collagen fibril assembly potentially offer new targets for anti-fibrotic 
treatments. Tissue weakening or altered collagen fibril morphologies, or both, are shared 
phenotypes of mice lacking matricellular thrombospondins. Thrombospondin-1 (TSP1) plays 
an indirect role in collagen homeostasis through interactions with matrix metalloproteinases 
and transforming growth factor-1 (TGF1). We found that TSP1 also affects collagen fibril 
formation directly.  Compared to skin from wild-type mice, skin from Thbs1-/- mice had 
reduced collagen crosslinking and reduced prolysyl oxidase (proLOX) abundance with 
increased conversion to catalytically active LOX. In vitro, TSP1 bound to both the C-
propeptide domain of collagen I and the highly-conserved KGHR sequences of the collagen 
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triple-helical domain that participate in cross-linking. TSP1 also bound to proLOX and 
inhibited proLOX processing by bone morphogenetic protein-1 (BMP-1). In human dermal 
fibroblasts (HDFs), TSP1 and collagen I colocalized in intracellular vesicles and on 
extracellular collagen fibrils, whereas TSP1 and proLOX colocalized only in intracellular 
vesicles. Inhibition of LOX-mediated collagen crosslinking did not prevent the extracellular 
association between collagen and TSP1; however, treatment of HDFs with KGHR-
containing, TSP1-binding, triple-helical peptides disrupted the collagen-TSP1 association, 
perturbed the collagen extracellular matrix, and increased myofibroblastic differentiation in a 
manner that depended on TGF receptor 1. Thus, the extracellular KGHR-dependent 
interaction of TSP1 with fibrillar collagens contributes to fibroblast homeostasis.  
 
INTRODUCTION  
 
Fibrillar collagens are abundant and essential components of the extracellular matrix 
(ECM) of connective tissues. The processing and secretion of collagen molecules and their 
initial assembly into fibrils has been studied extensively, yet knowledge of the cell and 
molecular mechanisms that regulate the organization of collagen fibrils within the ECM 
remains limited. This is of major importance for human health because fibrosis, the 
excessive and disorderly deposition of collagenous ECM by myofibroblasts as a result of 
tissue injury and repair, is a central and currently untreatable pathology in many chronic 
human diseases (1). Although the collagen family is quite extensive, the fibrillar collagens I, 
II, and III are the most abundant.  Collagens II and III are homotrimers, with three identical -
chains and separate gene products for each type. Each assembles as a right-handed triple 
helix.  Collagen I, the most widespread, differs in that it is comprised of two 1 chains and a 
single 2 chain.  Collagen II is the principal collagen of cartilage, whereas collagen I 
predominates in bone and tendon (2).  Collagens I and III both occur in skin and blood 
vessel walls, but collagen I is most abundant, and is the main focus of the present work. 
 
The synthesis of fibrillar collagens involves multiple steps of processing and post-
translational assembly (2). Each -chain is translated as a preproprotein from which the 
secretory signal peptide is cleaved upon co-translational entry into the lumen of the 
endoplasmic reticulum (ER). This is followed by steps important for stable assembly of the 
triple-helix: post-translational hydroxylation of lysine and proline residues and glycosylation 
of lysines (3). The C-propeptide domain guides -chain assembly into procollagen 
molecules, forming an in-register triple-helix and preventing premature intracellular fibril 
nucleation by restricting lateral packing (4). Upon secretion, the C-propeptide domain is 
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cleaved off mainly by bone morphogenetic protein 1 (BMP-1), and the N-propeptide is 
cleaved off by A Disintegrin and Metalloproteinase with Thrombospondin motifs  2 
(ADAMTS2), generating mature collagen molecules, consisting of the N- and C-telopeptides 
and the central triple-helical domain, that are competent for fibril assembly. In parallel, 
secreted prolysyl oxidase (proLOX) is also cleaved by BMP-1 to yield active mature (mLOX), 
which catalyzes oxidative deamination of lysine residues in the collagen N- and C-
telopeptides (3, 5). The resulting reactive lysine aldehydes target lysines or hydroxylysines 
of KGHR motifs within the triple-helix to cross-link and stabilize the assembled fibrils (6).  
 
In common with collagens, thrombospondins (TSPs) are amongst the most ancient 
and conserved components of the ECM (7). TSPs are matricellular proteins that have 
context- and tissue-specific roles through interactions with cell-surface receptors, growth 
factors, and other ECM proteins (8, 9). There are five TSPs in mammals (TSP1–5; TSP5 is 
also known as COMP, cartilage oligomeric matrix protein) and, in both humans and mice, 
tissue abundance of TSP1 and TSP2 increases with ageing, during which the ECM becomes 
less elastic and more rigid (10,11).  Rare polymorphisms in TSP1 have also been implicated 
in increased risk of cardiovascular disease (12, 13). TSP1 acts as an inhibitor of tumor 
growth (14) because it inhibits angiogenesis; however, the presence of TSP1 in tumor 
stroma may promote cell migration or ECM turnover, or both, leading to increased tumor 
metastasis (15). Increased abundance or extracellular deposition of TSPs, or both, also 
correlate with fibrotic events (16-18). Knockout mice have been reported for each individual 
TSP and show distinct tissue phenotypes and altered pathological susceptibilities that relate 
to altered cell-ECM interactions and signaling as well as effects on ECM properties (19-23). 
Mice lacking Thbs1, the gene that encodes TSP1, have increased vascular density in many 
tissues (24, 25), delayed wound healing, altered inflammatory responses, reduced 
abundance of active transforming growth factor- (TGF-) under various challenges, and 
increased susceptibility to tumor progression due to loss of the normal anti-angiogenic and 
p53-regulatory activities of TSP1 (26-28). An emerging coincident phenotype reported for 
Thbs1-/-, Thbs2-/-, Thbs4-/- and Thbs5-/- mice is disorganization of collagen fibril packing and 
altered fibril organization, manifested as increased cross-sectional areas of collagen fibrils in 
various tissues of young, healthy mice and correlated in several instances with mechanical 
weakening of the tissue (21-23, 29, 30). These phenotypes are reminiscent of tissue-specific 
alterations to collagen fibrils observed in dermis or tendons upon knockout of small leucine-
rich proteoglycans such as decorin or biglycan (31, 32). Similarly, mice lacking LOX also 
show impaired collagen fibril organization (33). LOX is a vital, copper-dependent enzyme 
with roles in ECM integrity, vessel wall mechanotransduction and tumor progression, that 
initiates extracellular cross-linking of collagen or elastin (34).  
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Investigations of the molecular basis for the TSP-null phenotypes have emphasized 
indirect regulatory mechanisms. For example, the activities of matrix metalloprotease-2 
(MMP-2) and MMP-9 are altered in Thbs1-/- and Thbs2-/- mice, and TSP1 and TSP2 bind to 
and inhibit the activities of these proteases in vitro (35-37). Cell type–specific effects on 
collagen transcription have also been noted: Thbs1-/- vascular cells have increased 
expression and secretion of collagen 1(I) and 2(I) chains (38), whereas the N-terminal 
domain of TSP1 increased collagen production and ECM assembly in vitro and in a sponge 
implant in vivo (39). Because TSP1 binds to and activates latent TGF- reduced TGF- 
signaling in tissues of Thbs1-/- mice also affects ECM properties (28, 40).  There remains a 
major gap in knowledge on the mechanisms of direct interaction of TSPs with fibrillar 
collagens and the importance of these in cell-ECM physiology. In vitro biochemical and 
electron microscopy studies have shown that several TSPs bind fibrillar collagens I, II, III and 
V, and TSP5 has also been shown to bind to collagen IX (41, 42). However, many of these 
studies relied on supra-physiological Zn2+ concentrations to demonstrate the protein-protein 
interactions (43).  
 
In view of the potential physiological importance of TSP-collagen interactions in ECM 
reorganization during ageing, tumour progression, tissue fibrosis, and other disease states, 
we have focused on TSP1 and set out to elucidate the molecular basis of interactions 
between TSP1 and fibrillar collagen. We quantified the status of fibrillar collagens and LOX 
in the skin of Thbs1-/- mice and examined the binding of TSP1 to native and denatured 
collagens, recombinant collagens and collagen-derived peptides, and a library of synthetic 
triple-helical peptides designated the “Collagen Toolkit” (44). The Toolkit peptides are 
homotrimeric, which simplifies their synthesis.  However, because there is much sequence 
homology between collagens I, II, and III, observations made using Toolkits II and III can 
often be applied directly to collagen I. We applied these findings to the physiological context 
of human dermal fibroblasts to examine the functional and regulatory roles of these 
interactions. Our data reveal that TSP1 participates in both intracellular and extracellular 
associations with fibrillar collagens that impact collagen cross-linking and fibroblast 
phenotype.  
 
 
RESULTS  
Abundance of collagen I and LOX is altered in the skin of Thbs1-/- mice  
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Collagen fibrils in the dermis of young, healthy Thbs1 knockout (Thbs1-/-) mice are 
characterized by irregular packing and increased cross-sectional areas (29). To investigate 
the underlying molecular basis, we examined eight-week old, male C57BL/6 and 
C57BL/6Thbs1-/- mice (38). We confirmed the Thbs1-/- status of the latter mice by 
immunoblotting extracts from spleen, a tissue that normally has high abundance of TSP1 
(Fig. 1A). We extracted collagens from the dermis of wild-type and Thbs1-/- mice with acetic 
acid, which releases fibrillar collagen molecules polymerized by aldimine cross-links, then 
measured the hydroxyproline content of these extracts to quantify collagen content. The 
acetic acid extracts from Thbs1-/- samples contained less hydroxyproline, an indication of 
altered collagen cross-linking, than samples from wild-type mice (Fig. 1B). Analysis by 
reducing SDS-PAGE and subsequent quantification revealed a significant decrease in 
collagen 2(I) monomers and altered proportions of cross-linked 1,2 dimers in Thbs1-/- 
samples compared to controls (Fig. 1C-1E). Because both of these features are indicative of 
altered collagen cross-linking, we examined the status of the major collagen cross-linking 
enzyme, lysyl oxidase (LOX), by immunoblotting of tissue extracts. The Thbs1-/- samples had 
significantly lower abundance of both proLOX, (the catalytically inactive LOX proprotein), 
and mature LOX (mLOX), the catalytically active form (Fig. 1F-H). The Thbs1-/- samples also 
tended to show an increased ratio of mLOX to proLOX (Fig. 1I). Collectively, these data 
implicated both TSP1-collagen I and TSP1-LOX interactions as possible mechanisms 
underlying the perturbations to collagen fibrils observed in Thbs1-/- mice.  
 
TSP1 inhibits proLOX cleavage and binds to multiple fibrillar collagens in vitro   
In view of the relative increase in mLOX relative to proLOX in Thbs1-/- skin, we examined in 
vitro whether TSP1 affects the processing of proLOX to mature LOX by the metallopeptidase 
bone morphogenetic protein-1 (BMP-1) (5). In in vitro proLOX cleavage assays, under 
conditions of partial proLOX cleavage, TSP1 inhibited BMP-1 activity in a concentration-
dependent manner but bovine serum albumin (BSA) did not (Fig. 2A, 2B). With regard to the 
above data and the complex processing of fibrillar procollagen that generates the mature 
collagen molecule (Fig. 2C), we next tested the binding of native TSP1 isolated from human 
platelets to different types and forms of fibrillar collagens in vitro by solid-phase binding 
assays. We tested TSP1 binding to denatured bovine collagen I; pepsin-extracted bovine 
collagens I and II from skin and trachea, respectively, or pepsin-extracted human collagen III 
from placenta and native collagen I fibrils isolated from equine tendon. Pepsin cleaves 
collagen molecules at the inner ends of the N- and C-telopeptides, thus leaving the triple-
helical domains in isolation (Fig. 2C).  Synthetic triple-helical Gly-Pro-Pro peptide (GPP10) 
(45) and BSA were included as negative controls, and all assays included [Ca2+] and [Zn2+] 
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in the physiological range. TSP1 bound equally well to pepsin-extracted collagens I, II, or III 
(Fig. 2D). However, as investigated with regard to collagen I, the binding of TSP1 was 
related to the molecular form of collagen, because we detected no specific TSP1 binding to 
denatured collagen I, moderate binding to pepsin-extracted collagen I, and strong binding to 
native, cross-linked collagen I fibrils that also include the N- and C-telopeptides (Fig. 2D). 
We also tested binding of TSP1 to recombinant trimers of the collagen C-propeptide domain 
(C-Pro as shown in Fig. 2C), which drives triple-helix assembly in fibrillar procollagens and 
also prevents inappropriate fibril formation intracellularly (2, 4). We observed concentration-
dependent binding of TSP1 to recombinant homotrimers of procollagen 1(I) C-propeptides 
(CPI), but not to recombinant homotrimers of procollagen 1(III) C-propeptides (CPIII) which 
shares 66% sequence identity with CPI (Fig. 2E). Binding of TSP1 to CPI depended on the 
presence of calcium, which is required for homotrimerization of the C-propeptides (4, 46) 
(Fig. 2F). Comparison of the concentration-dependence of TSP1 binding to CPI, pepsin-
digested collagen I, or a recombinant, homotrimeric “mini” procollagen I (rProCOL1A1; this  
protein includes the N-propeptide, N‑telopeptide, the 33 most N-terminal and 33 most C-
terminal Gly-Xaa-Yaa repeats, C-telopeptide and C-propeptide) demonstrated enhanced 
binding of TSP1 to the latter protein (Fig. 2G). Thus, TSP1 binding to procollagen I involved 
the CPI domain and at least one other binding site within the triple-helical region of this 
fibrillar collagen. 
 
TSP1 binds to specific peptides within the triple-helical domain of collagen II 
To identify the putative binding motif(s) for TSP1 within fibrillar collagen triple-helical 
domains, we screened purified human TSP1 against the Collagen Toolkit II, a library of 
triple-helical peptides that spans the entire triple-helical domain of homo-trimeric collagen II 
(44), by a solid-phase binding assay similar to enzyme-linked immunosorbent assay 
(ELISA). Specific Toolkit peptides were identified to bind TSP1 (Fig. 3A). We re-tested these 
candidate peptides in multiple independent experiments that included the additional negative 
control of adding the primary and secondary antibodies in the absence of TSP1 (Fig. 3B). 
Peptides II-5, II-44, and II-52 were confirmed to bind TSP1 in a specific and statistically 
significant manner (Fig. 3B) compared to GPP10. We also screened Collagen Toolkit III, a 
library of triple-helical peptides that spans the entire triple-helical domain of homo-trimeric 
collagen III (45) (FIG. S1A), and identified TSP1 binding to peptides III-5, III-52, and III-53 
greater than binding to GPP10, but this binding was lower than to the equivalent collagen II 
peptides (fig. S1B.  We tested whether binding of TSP1 to the collagen II peptides was 
affected by chelation of Ca2+ ions, because the 3-D structure of the C-terminal region of 
TSPs depends on bound Ca2+ ions (47-49). We found that TSP1 binding to peptide II-44 
7 
 
 
above background was abolished and binding to II-52 was greatly reduced in the absence of 
cations. Binding to peptide II-5 was highly variable in the presence of EDTA (Fig. 3C). 
Similar results were obtained with the Toolkit III peptides (fig. S1C). 
 
In view of a prior report that LOX binds to collagen fibrils (50), we also tested for binding of 
proLOX to TSP1, pepsin-digested collagen molecules, C-propeptides, rProCOL1A1, 
collagen I fibrils or TSP1-binding collagen triple-helical peptides. Under conditions in which 
we readily detected proLOX binding to TSP1, no specific binding of proLOX to pepsin-
digested collagen molecules or TSP1-binding collagen triple-helical peptides was detected 
(Fig. 3D). Notably, proLOX bound to CPI and rProCOL1A1, but not to CPIII, indicating the 
presence of a specific LOX-binding site within the CPI domain of procollagen I (Fig. 3D).  
 
The conserved KGHR site, involved in cross-linking of collagen molecules, is a 
minimum motif for TSP1 binding 
With the exception of peptide II-44, the Collagen Toolkit peptides that bound to TSP1 each 
contain a common amino acid sequence motif, KGHR (44). Therefore, we explored whether 
TSP1 binding depended on the KGHR motif, first by testing TSP1 binding to shorter 
derivatives of peptide II-52 that include the KGHR motif. TSP1 bound equally well to peptide 
II-52a, which contains four guest GXY triplets, peptides II-52b and II-52c, which contain 
three GXY triplets, and peptide II-52d, which consists of two GXY triplets, thus establishing 
GLKGHR as a minimum triple-helical region sufficient for TSP1 binding (Fig. 4A). The 
reduced binding of these short peptides relative to the longer peptide II-52 may reflect 
conformational differences in these very short regions of native sequence, or a possible 
positive contribution of a flanking sequence, as observed for the interaction between matrix 
metalloproteinase 13 and collagen II (51). Next, we tested versions of the GLKGHR peptide 
in which each residue, except for the glycine residues that are required to maintain the triple-
helical conformation, were mutated to alanine. Binding to TSP1 was maintained when 
leucine was replaced with alanine, and was abolished when any one of the lysine, histidine, 
or arginine residues was replaced with alanine (Fig. 4A).  Thus, an intact cluster of 
positively-charged residues was essential for TSP1-binding. Although not examined further 
in the context of this study, we noted that peptide II-44 contains the motif RGER and 
speculate that the closely-spaced arginine residues may explain the binding of TSP1 to this 
otherwise unrelated peptide.  
 
The KGHR motif occurs at only two sites within fibrillar collagens.  The N-terminal and C-
terminal KGHR sites are centered at or close to Gly88 and Gly931, respectively, of the 1014-
residue consensus triple-helical domain. In the fibrillar collagen chains of humans, the N-
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terminal motif is fully conserved in all collagens except for COL1A2, COL5A3, COL24A1, 
and COL27A1, which present variant KGIR, KGQR, KGLK or KGHK motifs, respectively 
(Fig. 4B). At the C-terminal site, the motif is conserved in most fibrillar collagens, yet is 
shifted by one GXY triplet and replaced by KGHN in COL1A2 and is disrupted in COL24A1 
and COL27A1 (Fig. 4B). KGHR motifs are also substantially conserved in various 
metazoans (52). 
 
KGHR peptides inhibit the binding of TSP1 to native collagen I fibrils 
The KGHR motif has a known role in the molecular cross-linking of mature collagen 
molecules as a target of reactive lysine aldehyde residues in the N- and C-terminal 
telopeptides that are generated by oxidative deamination by LOX (6). To determine if the 
TSP1-KGHR interaction identified here is physiologically relevant for TSP1 binding to native 
fibrillar collagen, we tested whether KGHR-containing, triple-helical peptides can inhibit 
binding of TSP1 to native, cross-linked collagen I fibrils isolated from equine tendons. We 
found that the non-TSP1–binding peptide II-8 (Fig. 3), had minimal inhibitory activity at all 
concentrations tested, whereas the KGHR-containing peptide II-52 showed concentration-
dependent inhibition with an approximate IC50 of 12.5 M (Fig. 4C). By examining the TSP1 
binding by indirect immunofluorescence, we found that, under control conditions, TSP1 
bound along the length of the fibrils in a punctate pattern (Fig. 4D, top row). In comparison to 
fibrils incubated with BSA, the TSP1 antibody reactivity depended on the addition of TSP1 
and was sensitive to the concentration of TSP1 (Fig. 4D, top row). Pre-incubation of TSP1 
with peptide II-8 before their application to collagen fibrils did not affect binding of TSP1 to 
fibrils (Fig. 4D), whereas pre-incubation of TSP1 with peptide II-52 substantially reduced 
TSP1 binding to fibrils (Fig. 4E). We found that an intact KGHR motif was necessary and 
sufficient for inhibition of TSP1 binding, as established by comparing the activities of 
GLKGHR, to which TSP1 binds specifically, or GLAGHR, which is not bound by TSP1 (Fig. 
4A). Only GLKGHR inhibited binding of TSP1 to fibrils effectively (Fig. 4F). These 
observations of TSP1 binding were substantiated by quantitative image analysis of fibrils 
from multiple experiments (Fig. 4G). 
 
TSP1 associates with fibrillar collagens and LOX in human dermal fibroblasts 
The above in vitro data and the strong binding of TSP1 to rProCOL1A1 indicated a complex 
collagen-regulatory mechanism of action for TSP1. Considering that procollagen processing 
and collagen fibril assembly depend on both intracellular and extracellular events, we turned 
to human dermal fibroblasts (HDFs) to identify the cellular sites where TSP1, fibrillar 
collagens, and LOX could potentially interact. Immunoblotting of cell extracts, conditioned 
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media, and isolated ECM from 24h to 96h cultures of HDFs detected time-dependent 
abundance of TSP1 in whole cell extracts (fig. S2A), conditioned media and isolated ECM 
(fig. S2B). Collagen I was detected in cell extracts and conditioned media throughout the 
time course of the experiments and in ECM at 96h. The CPI fragment was present in media 
but not in ECM (fig. S2A, S2B). Immunofluorescence using the LOX antibody, which detects 
both proLOX and mLOX, showed that proLOX predominated over mLOX in cell extracts, 
whereas mLOX and a sub-fragment thereof were detected transiently in conditioned media. 
No mLOX was detected in ECM (fig. S2A, S2B). By indirect immunofluorescence and 
confocal microscopy of HDFs between 48h and 96h after plating, when both intracellular and 
extracellular TSP1 was present, a major site of colocalization of TSP1 and fibrillar collagens 
was in intracellular vesicular structures (Fig. 5A, shown for 72h timepoint only). The 
association changed dynamically with time, increasing between 48h and 72h  (Fig. 5B, 
colocalization per cell quantified by Pearson correlation). Partial, heterogeneous 
colocalization of extracellular TSP1 with nascent collagen meshworks or protofibrils was also 
detected in non-permeabilized samples (Fig. 5A and Fig. 5C). At 72h and 96h, cellular LOX 
(corresponding mostly to proLOX, fig. S2A), colocalized with TSP1 in a subset of intracellular 
vesicles and colocalized in part with fibrillar collagens in intracellular vesicles (Fig. 5A, 5B). 
However, extracellular mLOX did not colocalize with collagen fibrils or TSP1 (Fig 5A, 5C).  
 
Because cross-linking of collagen fibrils by mLOX takes place over extended time periods 
(53), HDFs were also examined after 10 days of culture (Fig. 5D). At this time, we observed 
that the network of fibrillar collagen surrounding the cells was extensive and limited access 
for antibody staining, as indicated by the limited collagen staining seen with staining of non-
permeabilized cells and the detergent-resistant fibrillar network that was revealed by staining 
after permeabilization (Fig. 5D). In addition to amorphous and punctate deposits of TSP1, 
extracellular TSP1 colocalized in part with collagen fibrils (Fig. 5D, 5E). We did not detect 
colocalization of TSP1 and LOX, or LOX and fibrillar collagens, in either permeabilized or 
non-permeabilized cells  (Fig. 5D, 5E). Thus, TSP1-LOX and collagen-LOX associations in 
HDFs were limited to intracellular sites, where proLOX predominates, and appeared to 
correlate with early-stage cultures, whereas TSP1 and collagen colocalized in intracellular 
vesicles and extracellularly over time.  
 
To determine definitively whether fibrillar collagen or LOX associated with TSP1 in HDFs, we 
carried out in situ proximity ligation assays. This method uses antibodies to detect protein-
protein associations in situ within a ~40 nm radius (54). In HDFs cultured for 48 to 96 hours, 
TSP1 clearly associated intracellularly with fibrillar collagens, and this colocalization was 
limited to vesicular structures (Fig. 5F, 5G; fig. S3A). We found that extracellular association 
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of TSP1 and fibrillar collagens was restricted to discrete, extracellular patches and fibril-like 
structures and was maintained over time, reflecting associations within the ECM (Fig. 5F, 5H 
and fig. S3B). The intracellular association of TSP1 with LOX was also apparent over time 
(Fig. 5F, 5I, fig. S3A). Extracellularly, in line with the immunofluorescence results, a minor 
LOX-TSP1 association was detected above background (Fig. 5F, 5J) at times when mLOX 
was the predominant form of LOX and located extracellularly (fig. S2B). Also in line with the 
immunofluorescence data, intracellular association of LOX with fibrillar collagen in 
permeabilized HDFs was minor (fig. S3A), whereas no extracellular association was 
detected (Fig. 5F, 5K, 5L, fig. S3B). No signal was detected with single antibodies alone, or 
antibodies to vimentin and TSP1 as a pair of proteins predicted not to associate in HDF (fig 
S3C). Overall, these experiments in HDFs established that the major sites of colocalization 
of TSP1 with fibrillar collagen or LOX in HDFs were intracellular, and that TSP1 also 
associated, over extended periods of time, with extracellular collagen fibrils. 
 
The association of TSP1 and collagen I does not depend on LOX activity 
Given the colocalization of TSP1 with LOX in cells and the binding of TSP1 to the KGHR 
motifs, which are targets of reactive lysine aldehydes in collagen cross-linking, we 
determined whether inhibiting LOX activity with -aminoproprionitrile (APN) affected the 
ability of TSP1 to bind to collagen. We found that APN treatment altered the ratios of 
collagen and TSP1 in the deoxycholate-soluble and -insoluble fractions of HDFs and of 
soluble TSP1 in conditioned medium, whereas cellular LOX abundance was unchanged 
(Fig. 6A and 6B). As expected, APN resulted in fewer extracellular collagen fibrils (Fig. 6C). 
However, we established by both immunofluorescence (Fig. 6D) and by in situ proximity 
ligation (Fig. 6E, 6F), that TSP1 remained associated with the residual collagen fibrils. Thus, 
the interaction of TSP1 with fibrillar collagen did not depend on collagen cross-linking by 
LOX.  
 
Peptide II-52 inhibits the association between collagen and TSP1 in the ECM of 
fibroblasts  
To investigate the relevance of KGHR-dependent binding of TSP1 to fibrillar collagens in 
vitro to the associations of TSP1 with collagen in a cellular context, we treated HDFs for 48h 
or 72h with selected collagen triple-helical peptides at concentrations that effectively 
competed with collagen I for binding to TSP1 in vitro. By immunofluorescence of non-
permeabilized, control HDF cultures, we observed that nascent networks of collagen fibrils 
started to form after 48h (Fig. 6G), as expected (Fig. 5A). The colocalization of fibrils and 
TSP1 was retained in HDFs treated with peptide II-2, or the mutants GLAGHR or GLKGAR, 
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none of which bind to TSP1 (Fig. 6G, 6H). However, we found that collagen fibrils were more 
fragmentary and aggregated after treatment with either peptide II-52 or GLKGHR, and 
TSP1-collagen colocalization was decreased (Fig. 6G, 6H). Peptide II-52 was confirmed to 
decrease the extracellular association of TSP1 and fibrillar collagens by in situ proximity 
ligation (Fig. 6G, 6I), whereas the short GLKGHR peptide had a minor effect, possibly 
explained by its lower TSP1-binding activity. Thus, peptides that include an intact KGHR 
motif compete with cell-derived, collagenous ECM binding to TSP1, and reduced TSP1-
binding impacts on the organization of the collagen ECM.  
Peptide II-52 Increases myofibroblast differentiation through a TGF receptor I–
dependent mechanism  
Because KGHR-containing peptides perturbed collagen-TSP1 interactions in the ECM of 
fibroblasts and cell-ECM interactions are important regulators of myofibroblast differentiation 
(1), we examined possible physiological effects of KGHR-containing peptides on fibroblast 
differentiation. We first established conditions for the induction of two myofibroblast markers: 
fibronectin containing the alternatively-spliced domain, EDA (EDA-FN), and -smooth 
muscle actin (SMA), by TGF-1, a known inducer of myofibroblast differentiation in HDFs 
and measured the abundance of TSP1, LOX, and -catenin following TGF-1 treatment (fig. 
S4A–G). To determine whether TSP1-binding peptides influence the differentiation of 
myofibroblasts, we measured the abundance of SMA in cells treated for 96h with the 
TSP1-binding peptide II-52 or the non-TSP1-binding peptide II-8. II-52 specifically increased 
the number of SMA-positive cells, although to a lesser extent than did TGF-1, whereas 
peptide II-8 had no effect on the number of SMA-positive cells (Fig. 7A, 7B). Neither 
peptide altered HDF proliferation over time relative to vehicle treatment (Fig. 7C). The KGHR 
motif was important for the induction of SMA by II-52 because only the wild-type GLKGHR 
peptide increased the percentage of SMA-positive cells, whereas the peptides bearing the 
alanine substitutions in the motif did not (Fig. 7D, 7E). The GLKGHR peptide was less 
efficient than peptide II-52 at inducing SMA, likely because of the reduced TSP1-binding 
activity of GLKGHR compared to II-52. None of the peptides altered HDF cell numbers at 
96h (Fig. 7F).  
 
We also investigated whether the signaling process by which II-52 increases the number of 
SMA-positive cells is related to that of TGF- signaling pathways, which are the most 
widely-studied inducers of myofibroblast differentiation. We treated HDFs with an inhibitor of 
TGF- receptor 1 (TGFR1) kinase activity, SB-431542 (55), or an inhibitor of -catenin 
signaling, PNU-74654 (56), because -catenin signaling can also promote SMA 
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expression. First, we established effective concentrations of these compounds to inhibit the 
TGF−induced increases in EDA-FN and SMA protein abundance in HDFs (figs. S4A, 
S4B). Neither inhibitor affected the abundance of TSP1, but SB-431542 abolished the TGF-
1–induced increase in proLOX and mLOX abundance (figs. S4A, S4C, S4D-G).  SB-
431542 significantly reduced the induction of SMA by II-52 as well as by TGF- (Figs. 7G, 
7H), whereas PNU-74654 had a small effect on the percentage of SMA-positive cells only 
for TGF-1–treated cells (Figs. 7G, Fig. 7H). Thus, promotion of myofibroblast differentiation 
by II-52 is mediated by TGF-R1. To investigate whether this process related to the known 
role of extracellular soluble TSP1 as an activator of the latent TGF-1 complex (28, 40), we 
quantified bioactive and total (i.e., following exogenous acid activation) TGF-1 in media 
from HDF cultures treated with peptide II-8 or II-52 for 96h. Bioactive TGF1 was negligible 
under all conditions, and the addition of acid to the medium to activate TGF-1 did not 
indicate any differences in the abundance of total TGF-1 between the conditions (Fig. 7I). 
Thus the activity of II-52 in perturbing extracellular TSP1-collagen interactions also promotes 
myofibroblastic differentiation by a mechanism that does not relate to altered abundance of 
extracellular bioactive TGF1.  
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DISCUSSION  
The organization and cross-linking of fibrillar collagens is fundamental to tissue integrity. In 
many tissue settings, TSPs coincide with collagen-rich ECM, which suggests associations 
that might be highly relevant to normal tissue physiology and fibrotic pathologies. Here we 
elucidate that TSP1, the prototypic TSP family member, undergoes both intracellular and 
extracellular molecular interactions with fibrillar collagens. We show the latter to be important 
for control of myofibroblast phenotype. In vivo, in the dermis of Thbs1-/- mice, we observed 
altered cross-linking of fibrillar collagens, reduced abundance of proLOX and mLOX, and an 
increased ratio of mLOX to proLOX.  We established in vitro that TSP1 bound to proLOX, 
inhibited the cleavage of proLOX to mLOX by BMP-1, and bound to multiple sites on 
procollagen I molecules (the C-propeptide domain and the KGHR motifs, that are conserved 
in the triple-helical domains of collagens II and III). In cultured fibroblasts, TSP1 colocalized 
with collagen I and, to a lesser extent, LOX, in intracellular vesicles and also associated with 
extracellular collagen fibrils by binding the KGHR motif. The latter association promoted 
collagenous ECM organization and likely inhibits myofibroblastic differentiation. Treatment of 
cells with exogenous, KGHR-containing peptides promoted myofibroblast differentiation 
through a TGFR1-dependent process without altering the extracellular abundance of 
bioactive TGF. These data establish that TSP1 coordinates post-translational collagen I 
processing and assembly through multiple mechanisms that act at different stages of 
collagen fibril production, both intracellular and extracellular.  
 
The absence of TSP family members leads to disorganization of collagen fibrils in tissues of 
mice (4, 17, 25--27). By use of binding assays in vitro and demonstrations of protein 
localisations and colocalisations in cultured cells, we were able to identify specific 
interactions of TSP1 and then ascribe cellular contexts to these interactions. With regard to 
proLOX, we identified that TSP1 inhibited BMP-1–mediated cleavage of proLOX in vitro and 
associated in HDF only with intracellular LOX. Thus, BMP1 activity on proLOX may rise in 
the TSP1-null context, resulting in altered spatio-temporal aspects of proLOX production and 
thereby affecting collagen cross-linking.  Other studies have reported cardio-protective 
actions of intracellular TSP4 during endoplasmic reticulum stress within the endoplasmic 
reticulum of cardiomyocytes, but the status of LOX or collagen ECM organisation was not 
examined (57).  
 
We also investigated whether fibrillar collagens are both binding partners and substrates of 
LOX. We demonstrated, in vitro, specific binding of proLOX to CPI and rProCOL1A1, but not 
to CPIII, mature collagens, or KGHR-containing collagen triple-helical peptides. These data 
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suggest an interaction of proLOX with the CPI region of procollagen I prior to secretion. 
Consistent with this, collagen and LOX colocalized in HDF; however, in the absence of 
antibodies specific to proLOX or mLOX we could not determine whether this interaction is 
specific to proLOX. Free, extracellular CPI is present physiologically and has various 
functions (58, 59), and was detected in early-stage HDF cultures (fig. S2); however, mLOX 
only appeared in conditioned media after 48h. Our studies of non-permeabilized HDF at 10 
days did not detect any collagen-LOX association above background. This is in line with the 
transient, dynamic nature of LOX enzymatic interactions with collagen telopeptide lysine 
residues. 
 
With regard to binding of TSP1 to fibrillar collagens, we show that TSP1 exhibits dual direct 
binding to fibrillar intracellular procollagen I (containing the CPI domain and KGHR sites) as 
well as to mature, extracellular collagens I, II, and III (via KGHR sites). Given the increased 
collagen cross-linking in the Thbs1-/- context, it is relevant to consider that both mechanisms 
may limit the rate of homeostatic collagen cross-linking. TSP1 binding to the CPI domain 
could shield intracellular procollagen molecules from BMP-1 cleavage until secretion, or from 
active LOX, or both. TSP1 binding to the KGHR motif could protect KGHR motifs from cross-
linking by lysine aldehyde attack. We established that TSP1 bound to synthetic KGHR-
containing peptides as well as to native cross-linked collagen I fibrils, and that KGHR-
containing peptides inhibited TSP1 binding to native fibrils. Hence, the cross-linking of lysine 
residues does not appear to prevent TSP1 binding at this site. The enhanced TSP1 binding 
to collagen I fibrils relative to pepsin-digested collagen I suggests that the spatial 
presentation of KGHR sites may influence extracellular TSP1-binding, perhaps through 
increased avidity.  
 
Because TSP-1–binding triple-helical collagen peptides disrupted TSP1 binding to native 
collagen I fibrils (Fig. 4), we were able to explore the functional significance of collagen-
TSP1 associations in HDF. We focused on the early timepoints at which we had detected 
collagen-TSP1 or collagen-LOX associations (as in Fig. 5). KGHR-containing peptides 
markedly perturbed nascent collagen fibrils, resulting in aggregated collagen “patches”, 
greater variability in fibril size and shape, and reduced extracellular association of TSP1 and 
collagen I. KGHR-containing peptides also had specific effects on myofibroblast 
differentiation (Fig. 7). The induction of SMA by disruption of the TSP1-collagen interaction 
(using the TSP1-binding peptide, II-52) required TGF-R1 kinase activity, as established 
using specific inhibitors of either TGF-R1 or -catenin signaling. Although extracellular 
TSP1 is known to activate latent TGF1 (28), the application of II-52 did not increase the 
amount of extracellular bioactive TGF1 or total active TGF1.  These results are not 
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definitive, and the mechanism will require further investigation to determine whether the 
TSP1-collagen interaction inhibits signaling through TGF-R1; for example, by controlling 
the abundance or activity of TGF-R1. 
 
Known molecular partners of fibrillar collagens include fibril-associated collagens with 
interrupted triple helices (FACITs) (60), which align on the surface of the growing fiber and 
may restrict further recruitment of fibrillar collagen molecule, and the small leucine-rich 
proteoglycans (SLRPs). Different classes of SLRPs bind to different sites on the surface of 
collagen fibrils to modulate protofibril nucleation and the subsequent axial and lateral growth 
of fibrils (61). In common with TSP-knockout mice, mice null for individual SLRP family 
members are viable, but typically show tissue-specific alterations to collagen fibril structures 
and sizes. For example, mice lacking the SLRP fibromodulin (Fmod) have disorganized and 
smaller collagen fibrils in tendons and increased C-telopeptide cross-linking of collagen I 
(62-64). Fmod is proposed to facilitate extracellular collagen cross-linking because it binds to 
KGHR motifs in fibrillar collagens and binds and activates LOX without affecting LOX 
maturation (65, 66).  TSP1 and Fmod are the only ECM proteins identified to date that bind 
to the KGHR motif of fibrillar collagens, though binding of PEDF (pigment epithelium-derived 
factor) to collagen I depends on the arginine residue in this motif (67). Thus, TSP1 and 
Fmod bind the triple-helix of fibrillar collagens at a site distinct from the motifs recognized by 
the major collagen receptors and other collagen-binding proteins (68-70).  
 
Overall, the collective action of many ECM proteins on fibrillar collagens emphasizes the 
evolution of a complex network of mechanisms to control collagen fibril assembly and the 
activity of LOX.  The central conceptual advance of this study is the identification of an 
additional form of molecular control of fibrillar collagens. Our data reveal actions of TSP1 on 
fibrillar collagen, exemplified here by collagen I, at several steps during the molecular 
processing and assembly of collagen fibrils. Detailed studies will be needed to determine 
whether these activities influence procollagen trafficking, mask KGHR cross-linking sites, or 
control the spatio-temporal positioning of proLOX or its access to collagen molecules prior to 
secretion. The mechanism of action of TSP1 is unique in regulation of collagen homeostasis 
because it acts on both intracellular procollagen and proLOX as well as on extracellular 
fibrillar collagen.  
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MATERIALS AND METHODS 
Materials and Cells  
Normal human dermal fibroblasts (HDFs) from foreskins of healthy juveniles (C-12300, 
Promocell) were cultured in fibroblast growth medium (C-23010, Promocell) with 50g/ml L-
ascorbic acid and used for experiments between passages 3 and 8. Primary antibodies were 
used for detection of -smooth muscle actin (SMA), collagen I, EDA-fibronectin, TSP1; 
vimentin, collagen I, collagen 1 C-propeptide (CPI) (LF41) (71), and lysyl oxidase (LOX). 
Full details for each antibody are given in Table S1. Secondary antibodies were as follows: 
HRP-conjugated antibody recognizing mouse IgG or rabbit IgG; FITC-conjugated antibody 
for mouse IgG; TRITC-conjugated antibody for rabbit IgG (Table S2). Chemicals used and 
supplier information are listed in Table S3.  The following inhibitors were used: APN, 
SB431542, and PNU-74654 (full details are in Table S4). Purified and recombinant proteins 
used are listed in Table S5. Buffer compositions are given in Table S6.  
Sample preparation and collagen extraction from mouse skin  
Collagen was extracted from the skin of 8 week-old wild-type C57BL/6 male mice (JAX 
000664, Jackson Laboratory), n=4, and B6.129S2-Thbs1tm1Hyn/J male mice (JAX 00614, 
Jackson Laboratory), n=4. JAX 00614 mice were backcrossed to C57BL/6J for 8 
generations prior to establishment of the stock at Jackson Laboratory (19). 16 cm2 of skin 
was dissected from each mouse, shaved, any underlying adipose removed and samples cut 
into 3mm-wide strips. 2g skin/mouse was incubated with PBS containing protease inhibitor 
cocktail (2 mM NEM, 10 mM leupeptin, 20 mM pepstatin A), under rotation at 4ºC overnight 
and extracts collected as supernatants after centrifugation at 14000xg for 30min at 4ºC. 
Pellets were resuspended in 3ml of 0.5M acetic acid (HAc) containing protease inhibitor 
cocktail and incubated under rotation for 24h at 4ºC. Supernatants were collected after 
centrifugation at 14000xg for 30min at 4ºC to obtain the HAc-soluble fraction and Trizma 
base was added to bring the pH to 7, followed by hydroxyproline quantitation. Aliquots of 
acid-soluble collagens from each mouse, (corresponding to 250mol of hydroxyproline), 
were boiled in reducing SDS-PAGE sample buffer prior to analysis by SDS-PAGE.  
Hydroxyproline Quantitation  
Acid-extracted collagens were brought to a concentration of 600g/ml and subjected to 
hydrolysis with 6M HCl for 20h at 95ºC. Samples were centrifuged at 14000xg for 10min and 
supernatants diluted in dH2O to a final concentration of 4M HCl. Hydroxyproline assay kit 
was used according to manufacturer’s procedures (QuickZyme, Biosciences).  
ECM Proteins and Collagen Peptides  
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The following proteins were used (details, catalogue numbers and suppliers of proteins are 
listed in the Supplementary Table S5): recombinant human TGF1; purified human 
thrombospondin-1 (TSP1); recombinant human lysyl oxidase (proLOX); recombinant human 
mini-pro-collagen I alpha 1 (rProCOL1A1); denatured bovine collagen I; pepsin-digested 
collagens I, II, III; native collagen I fibrils; recombinant human procollagen C-propeptide I 
(CPI) and III (CPIII) homotrimers (4, 72). Collagens were dissolved overnight in 0.5M HAc to 
final concentrations of 1mg/ml or 5mg/ml. Collagen Toolkit II and derivative peptides were 
synthesised as C-terminal amides on TentaGel R RAM resin using Fmoc chemistry (44), but 
using CEM Liberty or Liberty Blue microwave-assisted solid phase synthesisers. Each guest 
sequence (27-residues for Toolkits or shorter sequences containing KGHR and its 
derivatives as indicated) is placed between GPC(GPP)5- and -(GPP)5GPC host sequences 
to stabilise the triple-helical conformation. GPP10, a negative control peptide (GPC-
[GPP]10GPC-NH2), represents the combined host sequence. All peptides were dissolved in 
10mM HAc at 5mg/ml final concentration. 
Solid-Phase Binding Assays  
Collagen triple-helical peptides at 10g/ml in 10mM acetic acid were coated onto wells of 96-
well plates (Immulon 2HB, 3455, ThermoFisher Scientific) overnight at 4°C. Collagen fibrils, 
pepsin-digested collagens, or denatured collagen I were adsorbed at saturating 
concentration of 10g/ml in 10mM acetic acid. In other experiments, wells were coated 
overnight at 4°C with TSP1 diluted in TBS containing 2mM CaCl2, or CPI or CPIII diluted in 
TBS/0.5mM CaCl2, each to a final concentration of 24nM or as indicated in individual figure 
panels. rProCOL1A1 was diluted in 10mM acetic acid to a final concentration of 24nM. All 
following steps were at room temperature (RT). Wells were blocked with 50g/ml BSA 
Fraction V. Test proteins in solution and primary or secondary antibodies were each diluted 
in Incubation Buffer (IB; Supplementary Table S6), containing either 2mM EDTA, or 2mM 
CaCl2 and 15mM ZnSO4. Antibodies were diluted as given in Supplementary Tables S1 and 
S2. All steps were performed for 1h, and each followed by three washes in IB. Final 
concentrations of proteins in solution were 8nM TSP1, or 24nM of rProCOL1A1, CPI or 
CPIII. For colorimetric detection, 100 l of a 1:1 mixture of TMB and 0.02 % H2O2 in citric 
acid buffer was added. Reactions were stopped with 100 l of 2M H2SO4 and absorbance 
measured at 450nm in a 96-well plate reader (M2/spectra max; Molecular Devices). As a 
negative control to confirm the specificity of each primary antibody, 8nM BSA was added in 
IB instead of the test protein. For competition assays, TSP1 was pre-incubated with 
increasing amounts of Toolkit peptides II-8, II-52 or selected derivatives (II-52d, II-52dK3A) 
for 1 h prior to adding to wells coated with collagen I fibrils and assays developed as 
described above.  
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ProLOX cleavage 
Recombinant proLOX (50 nM) was incubated without or with 0.18 nM recombinant human 
BMP-1, either in the presence of either 225nM BSA, or TSP1 at concentrations of 25nM, 
50nM, 110nM or 225nM, at 37 ºC for 15 minutes. Reactions were ended by addition of an 
equal volume of SDS-PAGE sample buffer and samples resolved on 10 % polyacrylamide 
gels under reducing conditions and immunoblotted for LOX or TSP1. ProLOX cleavage was 
quantified by measuring the pixel intensities of proLOX and mLOX bands using ImageJ 
software. Percentage of LOX cleavage was then calculated as follows: % of LOX cleavage = 
[(mLOX/proLOX)lane  / (mLOX/proLOX) from BMP1+ BSA condition] X 100.  
 
Fluorescence Microscopy 
For binding of TSP1 to fibrillar collagen, glass coverslips were coated with 60l of native 
collagen I fibrils (2g/ml in 0.01M HAc) overnight at 4°C. In some experiments, TSP1 (8nM 
in IB), was incubated with selected collagen triple-helical peptides for 1h at RT. Peptides 
used were: II-8, II-52, II-52d (GLKGHR peptide), or II-52dK3A (GLAGHR peptide), each at 
45M in 0.01M HAc, or the equivalent volume of 0.01M HAc as a negative control. All 
ligands and antibodies were diluted in IB containing 2mM CaCl2 and 15M ZnSO4. In 
parallel, collagen-coated coverslips were blocked with 5% BSA and then TSP1, without or 
with peptide, added for 1h, followed by anti-TSP1 for 1h, and then FITC-conjugated antibody 
to mouse IgG for 1h. All steps were followed by three washes in IB. Coverslips were washed 
and mounted in Vectashield (Vector Laboratories), and examined under a Leica DMI6000 
inverted epifluorescence microscope with a HCX PL APO 100X 1.40NA oil objective. XY 
images were captured with a DFC365FX Leica monochrome CCD camera run by Leica 
Application Suite X software (v3.0.2). TSP1 bound to collagen fibrils was quantified with 
Volocity 6.3 Software by: 1. selecting areas in phase contrast images that corresponded to 
collagen fibrils by finding objects with intensity values between 0 (lower) and 60 (upper); 2. 
finding objects bigger than 4m2 under the green fluorescence channel within the above fibril 
areas. The total fluorescence intensity in each area was then normalized over the pixel 
counts for the collagen fibril area. 
For localization of collagen I, lysyl oxidase, SMA and TSP1 in HDF, HDF (3x104 cells per 
well were plated onto 13mm glass coverslips for 48, 72 or 96h at 37°C. In some 
experiments, cells were treated with 15 M collagen Toolkit II peptides for either 48, 72 or 
96h. In other experiments, HDF were treated with 10 M SB-431542, 10 M PNU-74654 or 
the equivalent volume of DMSO for 30mins prior to addition of collagen Toolkit II peptides or 
2ng/ml TGF1 for 96h, or treated with 2 mM APN for 10 days.  For co-localization in non-
permeabilized cells, coverslips were fixed in 4% PFA. For permeabilization, cells were either 
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treated with methanol/acetone (1:1) or fixed in 2% PFA and permeabilized in 0.5% Triton-
X100 in PBS. All following steps were carried out at RT in a humidified chamber and each 
step was followed by three washes in PBS.  Coverslips were blocked with 1% BSA for 30 
min, then cells stained with the appropriate primary antibody(s) diluted in 2% BSA for 1h 
30min, and incubated for 1h with FITC-conjugated antibody to mouse IgG and then with 
TRITC-conjugated antibody to rabbit IgG, each diluted in PBS containing 5% BSA. 
Coverslips were washed and mounted as above. Cells were examined under an inverted 
Leica SP5-AOBS confocal laser-scanning microscope, with a HCX PL APO lambda blue 63x 
1.4NA oil objective. XY images were captured as Z stacks with a 0.25 m Z step size, with 
photomultiplier tube (PMT) detectors with a photocathode made of Gallium-Arsenide-
Phosphide (GaAsP) (Leica) for collecting light emission. Images were captured with Leica 
Application Suite AF software (v2.7.3.9723). For colocalization studies, Pearson correlation 
was measured in Volocity 6.3 software by the method of Costes to set automatic thresholds 
(73). At least 36 cells were analyzed per condition, per experiment. For non-permeabilized 
cells, Pearson correlation was measured per field; a minimum of 6 fields was taken for each 
condition in each independent experiment. For permeabilized cells (48h – 96h cultures), the 
Pearson correlation was measured for each cell. Around 80 cells were analyzed for each 
condition in each independent experiment.  In 10 days cultures, nuclei could not be counted 
accurately due to dense ECM and over-lapping of cells, therefore the Pearson correlation is 
reported per field. 
For in situ proximity ligation, HDF were plated onto 13mm glass coverslips, fixed, and 
incubated with primary antibodies as described above. In situ proximity ligation assays were 
performed using DUOlink (Sigma) according to the manufacturer’s instructions. Briefly, 
secondary antibodies coupled to cDNA probes were added for 1h at 37°C, then fluorescent 
detection was performed with Detection Reagents Green. Coverslips were examined under 
a Leica wide-field microscope (Leica DMI4000 B) and a HCX PL APO 63X 1.40NA oil 
objective. XY images were captured with a DFC310 FX Leica digital camera run by Leica 
Application Suite (LAS) X software (v4.5). Images were analyzed in ImageJ (Fiji). The 
intensity range was set between 37-255 intensity values. The total area of particles/field was 
measured and, dependent on the experimental design, the number of nuclei per field 
counted.  
 
Preparation of Cell Lysates and Supernatants  
HDF (4x105 cells) were cultured for 24, 48, 72 or 96 hours at 37°C. In some experiments 
cells were treated with 10 M SB-431542 or PNU-74654 or DMSO for 30min prior to addition 
of 2ng/ml TGF1 for 96h. Cells were lyzed in SDS-PAGE sample buffer to obtain total cell 
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extract, or with 2% deoxycholate buffer. Conditioned medium (CM) was harvested and 
mixed 1:1 with SDS-PAGE sample buffer. In parallel, heparin-binding proteins were collected 
from CM by incubation with 25l of Affi-gel® heparin beads for 90min with rotation at 4°C, 
followed by washing in PBS and resuspension of beads in SDS-PAGE-SB. For 
measurements of TGF1 activity, HDF were plated as for immunofluorescence microscopy 
and media harvested after 96h of culture, centrifuged to remove cell debris and 100l 
aliquots analyzed for active TGF1 by TGF1 Enzyme Immunoassay (Enzo, ADI-900-155), 
without or with acid activation of TGF1, according to manufacturer’s procedures. 
SDS-PAGE and Immunoblotting  
Proteins were resolved on 10% or 7.5% polyacrylamide SDS-polyacrylamide gels under 
reducing conditions. Gels were stained with Gel Code Blue Stain reagent. For 
immunoblotting, proteins were transferred to PVDF membrane (ISEQ00010, Immobilon-P, 
Millipore) and blocked in immunoblot Blocking Buffer (BB) overnight at 4°C. Membranes 
were probed with primary antibodies diluted in BB for 90min at RT under agitation. After 
three washes in BB, membranes were probed with appropriate HRP-conjugated secondary 
antibodies for 1h at RT, washed and incubated with Amersham ECL and signals detected on 
X-ray film (28906836, GE Healthcare). Protein levels from Coomassie-stained gels and 
immunoblots were quantified with NIH ImageJ software (Fiji), by boxing each lane and 
generating histogram plots showing peak areas corresponding to each band along the lane.  
Multiple sequence alignment   
Collagen sequences were obtained from NCBI proteins division. Multiple sequence 
alignments were prepared in MUSCLE 3.8 (74) at default parameters through the resources 
of EMBL/EBI (http://www.ebi.ac.uk/Tools/msa) and are presented in BoxShade 3.21 
(http://www.ch.embnet.org/software/BOX_form.html).  
 
Statistical analysis   
All experiments were carried out at least 3 times independently unless stated otherwise in 
the figure legend. Statistical tests were made in GraphPad Prism v5.01. Data were analyzed 
with D’Agostino-Pearson omnibus and Shapiro-Wilk tests to check for normal distribution. 
More than two groups of data were analyzed by one-way ANOVA with Bonferroni’s multiple 
comparison test.  Where distribution was not normal, two groups of data were analyzed by 
non-parametric Mann-Whitney test. More than two groups of data were analyzed by non-
parametric Kruskal-Wallis test with Holm’s correction. In the figures,  *** = p-value ≤ 0.0005; 
** = p-value ≤ 0.005; * = p-value ≤ 0.05. 
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Ethical Standards 
The experiments comply with the current laws of the country in which they were performed. 
 
SUPPLEMENTARY MATERIALS 
Fig. S1. Identification of specific TSP1-binding peptides within the triple-helical region of 
collagen III.   
Fig. S2. Detection of collagen I, TSP1, fibronectin, LOX and collagen I C-propeptide in cell 
fractions, conditioned media, and ECM isolated from human dermal fibroblasts. 
Fig. S3. Detection of the association of TSP1 with collagen I, collagen II, and LOX in HDF by 
in situ proximity ligation.  
Fig. S4. TGF-1–mediated induction of SMA in HDF.  
Table S1. Primary antibodies and the dilutions used in this study. 
Table S2. Secondary antibodies and the dilutions used in this study. 
Table S3. Chemicals used in this study. 
Table S4. Chemical inhibitors used in this study. 
Table S5. Proteins used in this study. 
Table S6. Buffers used in this study. 
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FIGURE LEGENDS  
 
Figure 1. Fibrillar collagens and LOX in skin samples from wild-type and Thbs1-/- mice. 
(A) Immunoblots showing TSP1 in spleen samples from wild-type (WT) and Thbs1-/- mice (4 
mice of each genotype, numbered 1-4). Ponceau staining of the gel used for immunoblotting 
is shown as a loading control. (B) Hydroxyproline content of acetic acid extracts from WT 
and Thbs1-/- skin samples. N = 4 for each genotype. (C) SDS-PAGE analysis of acid-
extracted collagens from skin of WT and Thbs1-/- mice under reducing conditions. The 
samples were equalized for hydroxyproline content. Bands corresponding to various forms of 
collagen trimers, dimers, and monomers are noted. N = 4 for each genotype. (D) 
Quantification of collagen 2(I) in WT and Thbs1-/- samples. N = 4 for each genotype. (E) 
Proportions of different collagen forms extracted from skin of WT and Thbs1-/- mice, 
including mean ± S.D. N = 4 animals per genotype. (F) Immunoblot showing proLOX and 
mLOX in total skin extracts from WT and Thbs1-/- mice.  Ponceau staining of the gel used for 
immunoblotting is shown as a loading control. N = 4 for each genotype. (G, H) Quantification 
of proLOX (G) and mLOX (H) from immunoblots, normalized to the major loading control 
band. N = 4 for each genotype. (I) mLOX/proLOX ratio from the quantitations in panels G 
and H (p = 0.057). In each scatter plot, the bar indicates the mean. Data were analyzed by 
Mann-Whitney U-test. Each dot in panels B and D represents the value from an individual 
animal. Each dot in panels G, H, and I represents the mean of 4 separate measurements 
from each animal. 
 
Figure 2. TSP1 binds to proLOX and fibrillar collagens I, II and III in vitro.  
(A) Representative immunoblots of assays for cleavage of recombinant human proLOX by 
BMP1 in the absence or presence of increasing concentrations of TSP-1, as indicated. BSA 
was used as a negative control. N = 3 independent experiments. (B) Quantification of the 
concentration-dependent inhibition of BMP-1–mediated proLOX cleavage by TSP1. Each 
data point represents the mean from 3 independent experiments, and the error bars indicate 
s.e.m. (C) Schematic diagram of the domains of a fibrillar procollagen molecule. (D) Binding 
of TSP1 to immobilized collagens in solid-phase binding assays. Col I (denatured), Col I, Col 
II, and Col III samples were derived from pepsin-digested collagen preparations. GPP10 and 
BSA were included as negative controls. One-way ANOVA and Bonferroni’s multiple 
comparison test was performed against GPP10. N = 4 independent experiments. (E) 
Concentration dependence of TSP1 binding to the indicated immobilized proteins (ligands). 
The ligands (CPI or CPIII) were immobilized and incubated with or without TSP1 (T). A 
mouse antibody recognizing TSP1 (C9) and goat anti-mouse antibody (GAM) were included 
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in each reaction to quantify binding. N = 4 independent experiments. (F) Solid-phase binding 
assays testing TSP1 (T) binding to immobilized CPI or BSA in the presence of either Ca2+ or 
EDTA and quantified with the antibodies C9 and GAM. N = 4 independent experiments. 
One-way ANOVA and Bonferroni’s multiple comparison test was performed against BSA. 
(G) Concentration dependence of TSP1 (T) binding to the indicated immobilized proteins 
(ligands), rhProCOL1A, Col I, and CPI. Antibodies C9 and GAM were used to quantify 
binding. N = 4 independent experiments.  Dotted lines in E and G indicate negative control 
assays without TSP1. Data points in D–G indicate the mean, and error bars indicate the 
s.e.m. 
 
Figure 3. Identification of specific TSP1-binding peptides within the triple-helical 
region of collagen II.  (A) Quantification of the binding to TSP1 to the 56 peptides 
(numbered for every fifth peptide as II1, etc) of the Collagen Toolkit II in the presence of Ca2+ 
and Zn2+. The horizontal line represents the background binding to GPP10. Each bar 
represents the mean of duplicate samples. (B) Binding of TSP1 (T) to specific TSP1-binding 
peptides as identified from the initial hits in Toolkit II in the presence of Ca2+ and Zn2+. 
Binding was quantified by indirect colorimetric assay using the antibodies C9 and GAM. N = 
4 independent experiments. (C) Quantification of the binding of TSP1 (T) to the indicated 
peptides in the presence of the Ca2+ chelator EDTA. N = 4 independent experiments. (D) 
Binding of proLOX to immobilized TSP1 and the indicated proteins and peptides derived 
from fibrillar collagen. N = 4 independent experiments. In all panels, GPP10 and BSA were 
included as negative controls. Pepsin-digested collagens I and III were used as positive 
controls in B and C. In B–D, one-way ANOVA and Bonferroni’s multiple comparison tests 
were performed against GPP10. Each bar indicates the mean, and error bars indicate the 
s.e.m.  
 
Figure 4. KGHR is a minimal and conserved motif for TSP1 binding.  
(A) Binding of TSP1 (T) to derivatives of TSP1-binding peptides from the Collagen Toolkit II, 
truncated or mutated as indicated (guest peptides). Binding was quantified by indirect 
colorimetric assay using the antibodies C9 and GAM. Data are from 5 independent 
experiments. (B) Alignment showing the KGHR motifs (red text) in the N-terminal and C-
terminal triple-helical regions of the indicated collagen chains of Homo sapiens (Hs). The 
numbers 87 and 930 refer to the amino acid position in the triple-helical domain of collagen 
1(I). Black shading, identical residues; grey shading, conservative substitutions; no 
shading, no conservation. (C) Quantification of TSP1 binding to the indicated Collagen 
Toolkit II peptides II-8 or II-52. Each data point represents the mean, and bars represent the 
s.e.m. of 3 independent experiments.  (D–F) Merged phase-contrast and 
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immunofluorescence images of TSP1 binding to collagen I fibrils isolated from tendons (D); 
TSP1 binding to collagen I fibrils in the presence of the indicated Collagen Toolkit II peptides 
(E), or in the presence of peptides of the indicated sequence (F). Images are representative 
of 4 independent experiments. Scale bar, 15 m. (G) Quantification of immunofluorescence 
staining for TSP1 bound to collagen fibrils, calculated as total fluorescence intensity within 
fibrils normalized on pixel count within fibrils. Each dot represents the value from an 
individual experiment, each bar indicates the mean, and the error bars indicate the s.e.m. 
from 4 independent experiments.  Data were analyzed by Kruskal-Wallis test and pairwise 
tests against BSA with Holm’s correction. 
 
Figure 5. Localization of TSP1, fibrillar collagen and LOX in human dermal fibroblast 
cultures. (A) Dual indirect immunofluorescence staining of the indicated pairs of proteins in 
permeabilized or non-permeabilized human dermal fibroblasts (HDF) cultured for 72h. The 
regions shown at higher magnification in the inset panels are boxed by dotted lines in the 
main panels. Nuclei were stained with DAPI (blue). Images are representative of 4 
independent experiments. (B) Quantification by Pearson correlation (per cell) of 
colocalization of the indicated pairs of proteins in permeabilized (P) HDF cultures at the 
indicated times. C, collagen I; T, TSP1; L, LOX. N = 4 independent experiments with at least 
36 cells analyzed per condition per experiment. Data were analysed by Kruskal-Wallis test 
and Dunn’s comparison. (C) Quantification by Pearson correlation (per field) of colocalization 
of the indicated pairs of proteins in non-permeabilized (NP) HDF cultures at the indicated 
times. N = 4 independent experiments with at least 6 fields analyzed per condition per 
experiment. (D) Dual indirect immunofluorescence staining of the indicated pairs of proteins 
in permeabilized and non-permeabilized HDF after 10 days of culture. Images are 
representative of 4 independent experiments. The regions shown at higher magnification in 
the insets panels are boxed by dotted lines in the main panels. (E) Quantification by Pearson 
correlation (per field) of colocalization of the indicated pairs of proteins in HDF after 10 days 
of culture. N = 4 independent experiments with at least 6 fields analyzed per condition per 
experiment.  (F) In situ proximity ligation assay for the indicated pairs of proteins in HDF 
cultured for 72h. Images are representative of 4 independent experiments. (G-L) 
Quantification of in situ proximity ligation signals for the indicated pairs of proteins over time 
in permeabilized (P) or non-permeabilized (NP) HDF. 2Ab, secondary antibodies only. Each 
data point represents the mean from one experiment, and the bars indicate the mean. N = 4 
independent experiments (G–J), N = 3 independent experiments (K–L). At least 36 cells 
were analyzed per condition for each experiment. Panels A, D and F show results for HDF at 
passage 7 and are representative of 4 experiments on HDF between passages 4 and 8. 
Scale bars, 50 m (main image) and 10 m (insets).  
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Figure 6. Effects of LOX inhibition or KGHR-containing peptides on the localization of 
TSP1 and fibrillar collagen in human dermal fibroblast cultures. (A) HDF were cultured 
for 10 days in the absence or presence of the LOX inhibitor APN. The soluble and insoluble 
fractions of cell extracts and conditioned medium (CM) from each treatment group were 
analysed by immunoblotting for collagen I (l), TSP1, and proLOX. GAPDH is a loading 
control. Molecular markers are indicated to the left of the blots in kDa. (B) Quantification of 
the indicated proteins from the immunoblots in (A). Protein abundances were normalized to 
GAPDH and expressed as a ratio versus control cells.  Each bar represents the mean of 3 
independent experiments, and the error bars indicate s.e.m. Mann-Whitney tests were 
performed for each pair (not significant). (C) Indirect immunofluorescence images showing 
TSP1 and collagen I in HDF cultured for 10 days in the absence or presence of APN. 
Nuclei were stained with DAPI (blue). Images are representative of 4 independent 
experiments. The regions shown at higher magnification in the insets panels are boxed by 
dotted lines in the main panels. (D) Quantitation by Pearson correlation (per field) of 
colocalization of TSP1 and collagen I under the indicated conditions. N = 4 independent 
experiments with at least 36 cells analyzed per condition per experiment. (E) In situ proximity 
ligation assays in permeabilized HDF after 10 days culture in the absence or presence 
of APN. Images are representative of 4 independent experiments. (F) Quantitation of 
proximity ligation signals under the indicated conditions. N = 4 independent experiments with 
at least 36 cells analyzed per condition per experiment. (G) Immunofluorescence showing 
collagen and TSP1 in HDF cultured and treated for 48h with the indicated peptides, then 
fixed and stained by indirect immunofluorescence (IF) or in situ proximity ligation 
(Prox). HAc, acetic acid.  In the upper row, the regions shown at higher magnification in the 
insets panels are boxed by dotted lines in the main panels. Each row is representative of 4 
independent experiments. (H) Quantification by Pearson correlation of 
immunofluorescence colocalizations as in G. N = 4 independent experiments with at least 36 
cells analyzed per condition per experiment. (I) Quantification of proximity ligation signals 
for conditions as in G.  N = 4 independent experiments with at least 36 cells analyzed per 
condition per experiment.  Data in H and I were analyzed by Kruskal-Wallis test and pairwise 
tests against HAc with Holm’s correction. Scale bars, 50 m (main image) and 10 m 
(insets). 
 
Figure 7. KGHR-containing, TSP1-binding collagen triple-helical peptides increase 
myofibroblast differentiation through a TGF-RI–dependent mechanism.   
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(A) Merged immunofluorescence images of HDF cultured for 96h in the presence of HAc, 
TGF-1, collagen peptide II-8, or collagen peptide II-52 and stained for SMA (green) and 
nuclei (DAPI, blue). Images are representative of 3 independent experiments. (B) 
Quantification of the percentage of SMA-positive cells under the indicated conditions from 
3 independent experiments. (C) Effects of the various treatments on cell numbers over time, 
N = 3 independent experiments. (D) Merged immunofluorescence images showing SMA 
(green) and DNA (blue) in HDF cultured for 96h in the presence of HAc, TGF-1, or the 
indicated peptides. Images are representative of 3 independent experiments. (E) 
Quantification of SMA-positive cells per field following treatment with the indicated 
peptides. N = 3 independent experiments. (F) Effects of the indicated peptides on cell 
numbers at 96h. N = 3 independent experiments. (G) Merged immunofluorescence images 
showing SMA (green) and DNA (blue) in HDF cultured for 96h in the presence of the 
inhibitor of TGFR1 kinase activity SB-431542 (SB) or the -catenin signaling inhibitor PNU-
74654 (PNU). Images are representative of 3 independent experiments. (H) Quantification of 
SMA-positive cells after 96h in the presence of the indicated inhibitors. N = 3 independent 
experiments. (I) Quantification of bio-active and total (determined after acid activation) active 
TGF1 in media from HDF cultured in the presence of the TSP1-binding peptide II-52. N= 3 
independent experiments with duplicate samples per condition per experiment. In all graphs, 
each data point indicates the mean, and error bars indicate the s.e.m. In B, C, E, F and H, at 
least 30 cells were scored per condition per experiment.  Data were analyzed by Dunnett’s 
multiple comparison test (one-way ANOVA) against HAc (B) or by Kruskal-Wallis test and 
pairwise tests against HAc (E and F), or against DMSO (H). Scale bars, 50 m (main image) 
and 10 m (insets). 
 
 
 
